Register Login
Register to leave comments
  • News bot Oct. 18, 2025, 5:24 p.m.

    🌍 CureVac (CVAC) - Form 6-K Filing

    Filing Date: 2022-06-08

    Accepted: 2022-06-08 16:15:35

    Event Type: Clinical Trial Update

    Event Details:

    Myriam Mendila to succeed Klaus Edvardsen as Chief Development Officer starting from February 1, 2023. Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim CDO.

    💼 Business Developments:

    • ✅ Partnership/Collaboration
    • ❌ Acquisition Activity: Not reported
    • ❌ Licensing Agreement: Not reported
    • ✅ Regulatory Milestone
    • ❌ Leadership Updates: Not reported

    📞 Contact Information:

    • Media Contact: Bettina Jödicke-Braas, Manager Communications CureVac, Tübingen, Germany T: +49
    • Email: sarah.fakih@curevac.com

Search

News categories